Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma

Recent studies have focused on regulatory T cells (Tregs) in chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC) and they were also conducted independently of each other.

[1]  Jun‐liang Fu,et al.  Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma , 2010, Journal of Gastroenterology.

[2]  Antonio Bertoletti,et al.  A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. , 2010, Journal of hepatology.

[3]  Birgitta Sander,et al.  A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1–Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages , 2010, Clinical Cancer Research.

[4]  S. Qiu,et al.  Human Leukocyte Antigen-G Protein Expression Is an Unfavorable Prognostic Predictor of Hepatocellular Carcinoma following Curative Resection , 2009, Clinical Cancer Research.

[5]  Zhao-You Tang,et al.  Combination of peritumoral mast cells and T‐regulatory cells predicts prognosis of hepatocellular carcinoma , 2009, Cancer science.

[6]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[7]  E. Kuipers,et al.  Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. , 2008, Clinical immunology.

[8]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[9]  E. Winer,et al.  Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Zhi Chen,et al.  Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection , 2008, Immunology.

[11]  I. Sheen,et al.  Liver injury is associated with enhanced regulatory T‐cell activity in patients with chronic hepatitis B , 2007, Journal of viral hepatitis.

[12]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Zheng Zhang,et al.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. , 2007, Gastroenterology.

[14]  M. Yuen,et al.  Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels , 2007, Gut.

[15]  E. Kuipers,et al.  Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. , 2007, Virology.

[16]  S. Hirohashi,et al.  FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis , 2007, Clinical Cancer Research.

[17]  Boping Zhou,et al.  Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. , 2006, International immunology.

[18]  Z. Zou,et al.  Circulating and Liver Resident CD4+CD25+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B1 , 2006, The Journal of Immunology.

[19]  Zhijian Yao,et al.  Estrogen Receptor α Polymorphisms Associated With Susceptibility to Hepatocellular Carcinoma in Hepatitis B Virus Carriers , 2006 .

[20]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[21]  T. Okanoue,et al.  Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas , 2005, Gut.

[22]  Y. Liaw,et al.  Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[23]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[24]  E. Kuipers,et al.  Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection , 2005, Hepatology.

[25]  Kyong‐Mi Chang.  Regulatory T cells and the liver: A new piece of the puzzle , 2005, Hepatology.

[26]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[27]  A. Muñoz,et al.  Specific mutations of hepatitis B virus in plasma predict liver cancer development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Josep Fuster,et al.  The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[29]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[30]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[31]  P. Vajro,et al.  Practice Guidelines Management of chronic hepatitis B in childhood : ESPGHAN clinical practice guidelines , 2013 .

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[34]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[35]  Zhijian Yao,et al.  Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. , 2006, Gastroenterology.

[36]  Roger Williams,et al.  Modulation of the CD8 -T-Cell Response by CD4 CD25 Regulatory T Cells in Patients with Hepatitis B Virus Infection , 2005 .

[37]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.